Association Between Hemoglobin-Creatinine Ratio and Six-Month All-Cause Readmission in Chinese Patients with Heart Failure: A Retrospective Cohort Study
A simple math formula using standard blood tests predicts which heart failure patients risk readmission, enabling better discharge planning.
This retrospective cohort (n=1,833) demonstrates that the hemoglobin-creatinine ratio — a simple composite biomarker reflecting combined anemia and renal dysfunction — independently predicts 6-month all-cause readmission after heart failure hospitalization, with a graded inverse relationship. The HBCR requires no additional testing beyond standard admission labs and could enhance pre-discharge risk stratification.
What the study was
- Study design
- Retrospective cohort study
- Population
- Adults hospitalized with heart failure in China
- Sample size
- 1833
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Archives of Medical Research
Why it surfaced
HBCR is a zero-cost, readily calculable composite biomarker from standard admission labs that independently predicts HF readmission with a clinically meaningful effect size. HF readmission is a major healthcare burden and quality metric. External validation needed but this is a plausible immediately implementable risk tool.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.